Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions (Q57825105)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 June 2014

Language	Label	Description	Also known as
English	Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions	scientific article published on 27 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

based on heuristic

inferred from title

drug interaction

0 references

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Anne M Filppula

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Tuija Tapaninen

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

O Kailari

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

P J Neuvonen

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

M Neuvonen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

0 references

publication date

27 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

96

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

498-507

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Grapefruit juice inhibits the metabolic activation of clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Gemfibrozil greatly increases plasma concentrations of cerivastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Impact of OATP transporters on pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Drug interaction studies: study design, data analysis, and implications for dosing and labeling

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Determinants of Cytochrome P450 2C8 Substrate Binding: STRUCTURES OF COMPLEXES WITH MONTELUKAST, TROGLITAZONE, FELODIPINE, AND 9-CIS-RETINOIC ACID

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2014.141

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57825105&oldid=2125865232"